| Literature DB >> 11237062 |
S Bailey1, A G Hall, A D Pearson, C P Redfern.
Abstract
Glucocorticoids are used in the treatment of acute lymphoblastic leukaemia (ALL) and chronic lymphocytic leukaemia (CLL) but many patients develop glucocorticoid resistance on relapse. The ligand-activated glucocorticoid receptor inhibits activity of the AP-1 transcription factor and the purpose of this study was to test the hypothesis that up-regulation or overexpression of AP1-binding activity may be an important mechanism of glucocorticoid resistance in ALL and CLL. In vitro sensitivity of patient blasts to prednisolone was measured using thEntities:
Mesh:
Substances:
Year: 2001 PMID: 11237062 DOI: 10.1038/sj.leu.2402039
Source DB: PubMed Journal: Leukemia ISSN: 0887-6924 Impact factor: 11.528